Harmar D. Brereton:
Harmar D. Brereton, M.D.,
M.D. Degree: University of Pittsburgh School of Medicine
Residency: National Cancer Institute
Fellowship: Johns Hopkins Hospital
Board Certification: Internal Medicine, Medical Oncology, Hematology, and
D. Brereton Dr. Harmar D. Brereton is a founding partner of the radiation oncology physician group,
Radiation Medicine Associates of Scranton (RAMAS), and CEO of RAMAS. He earned
his undergraduate degree from Yale University, New Haven, CT, and his Medical
Doctorate from the University of Pittsburgh School of Medicine, PA.
He completed his internship and residency at Grady Memorial Hospital, Atlanta,
GA, before becoming a clinical associate at the National Cancer Institute,
Bethesda, MD, and an instructor in medicine at Georgetown University Hospital,
Washington, D.C. He completed a Radiation Oncology Fellowship at The Johns
Hopkins Hospital, Baltimore, MD.
Dr. Brereton is Board Certified in Internal Medicine, Radiation Oncology, Medical
Oncology, and Hematology.
He serves on staff at eleven Northeastern Pennsylvania hospitals. In addition, he is a
clinical professor of medicine at The Commonwealth Medical College in Scranton.
Recognized in the medical and general community for his vision and leadership,
Dr. Brereton established Northeast Radiation Oncology Center (NROC), a cancer
treatment center that is a collaboration between the physicians of RAMAS and
Community Health Systems. NROC provides the most advanced radiation cancer
treatment and research available in the region. In addition, he has developed a network
of oncology centers caring for more than 2,000 patients each year, serving over 22
hospitals in Pennsylvania, New York and New Jersey.
He also is the founder of the Northeast Regional Cancer Institute (NRCI), a regional
non-profi t consortium of hospitals dedicated to cancer research and education, and he
helped introduce a Radiation Therapy Oncology Group (RTOG) cancer research program
sponsored by the National Cancer Institute which offers state-of-the-art clinical
research trials for people in the Pennsylvania, New York and New Jersey service area.